好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Brain Degeneration in ALS vs ALS-FTD is Not on a Continuum as Revealed by MRI White Matter Graph Theory Network Analysis
Neuromuscular and Clinical Neurophysiology (EMG)
Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)
091

To determine (1) which, if any of the cALS, ALS-CST+, ALS-CST–, or ALS-FTD patient subgroups share regional WM abnormalities, and (2) whether ALS and ALS-FTD are on a continuum.

Four subgroups of ALS patients were identified by clinical assessment and routine neuroimaging assessment: (1) classic ALS (cALS) with upper motor neuron (UMN) and lower motor neuron (LMN) signs, (2) upper motor neuron-(UMN-) predominant ALS with hyperintensity of the corticospinal tract (ALS-CST+), (3) UMN-predominant ALS without CST hyperintensity (ALS-CST–), and (4) ALS with frontotemporal lobe dementia (ALS-FTD). Some1,2 but not all3,4 studies have shown ALS and ALS-FTD to be on a continuum.

An exploratory whole brain white matter (WM) network analysis was performed using graph theory approach. Diffusion tensor MRI data were obtained for 83 ALS patients (cALS n=25, ALS-CST+ n=19, ALS-CST– n=24, ALS-FTD n=15) and 14 neurologic controls.

Brain regions showing significant differences in degree (WM network) measures between ALS patients with or without FTD and neurologic controls included: prefrontal, motor, extra motor, subcortical and cerebellar regions. WM networks affected by ALS degeneration were noticeably different between cALS, ALS-CST+, ALS-CST–, and ALS-FTD groups, although with some overlaps, particularly in ALS-CST+ and ALS-FTD groups.

Of the few brain regions sharing WM abnormalities between patient groups: (1) more were found in the cerebellum than in the forebrain of those with cALS, ALS-CST+, or ALS-CST–; (2) only three occurred in all four groups, including ALS-FTD patients. Despite some overlap, distinct regional involvement in cALS, ALS-CST+, ALS-CST–, and ALS-FTD patients does not support a continuum between the subgroups and suggests differential patterns of WM neurodegeneration between these ALS phenotypes.

Authors/Disclosures
Erik P. Pioro, MD, DPhil, FAAN (University of British Columbia)
PRESENTER
Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avanir Pharmaceutical, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx Pharmaceuticals. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma America, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroTherapia, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT Pharma America, Inc..
Erik P. Pioro, MD, DPhil, FAAN (University of British Columbia) Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avanir Pharmaceutical, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx Pharmaceuticals. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma America, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NeuroTherapia, Inc.. Dr. Pioro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT Pharma America, Inc..